Filing Flows › GeneDx Holdings (WGS) › Q2 2026
GeneDx Holdings (WGS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
GeneDx Holdings (WGS) reported revenue of $114M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +12% from the quarter before. Operating margin was -15.3%, net loss $17.7M (15.5% of revenue).
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $114M | +12% | +11% |
| Operating profit | −$17.5M | — | -295% |
| Net earnings | −$17.7M | — | -264% |
| Operating cash flow | −$29.0M | — | -378% |
What changed
Revenue was $114.4M in Q2 2026, up 11% year over year and up 12% from the previous quarter. Patients with third-party insurance was the largest line at 83% of revenue. Patients with third-party insurance added $13.6M year over year (up 17%), 116% of the total change. Institutional customers declined 14%.
Gross margin was 68.4%, down 0.7 points from Q2 2025. Operating costs exceeded revenue by $17.5M, an operating margin of -15.3%. Operating expenses grew 54% against revenue growth of 11%. The fastest-growing cost line was Research & development (+30%). The quarter ended with a net loss of $17.7M, narrower than the previous quarter's $63.3M loss.
Operating cash flow was −$29.0M. Non-cash charges added back $6.7M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items used $24.3M. Capital expenditures of $10.1M exceeded it, leaving free cash flow of −$39.1M.
Questions
What was GeneDx Holdings' revenue in the second quarter 2026?
GeneDx Holdings (WGS) reported revenue of $114M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +12% from the quarter before.
Was GeneDx Holdings profitable in the second quarter 2026?
Operating loss was $17.5M (-15.3% of revenue) and net loss $17.7M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.